SiRNAs targeted to Smad4 prevent renal fibrosis in vivo

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Morishita, Yoshiyuki ^a   Yoshizawa, Hiromichi ^a   Watanabe, Minami ^a   Ishibashi, Kenichi ^b   Muto, Shigeaki ^a   Kusano, Eiji ^c   Nagata, Daisuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^c Utsunomiya Social Insurance Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; SMAD4 PROTEIN; SMAD4 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; FIBROSIS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; METABOLISM; MOUSE; MYOFIBROBLAST; PATHOLOGY;

ANIMALS; FIBROSIS; FOLIC ACID; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; MICE; MYOFIBROBLASTS; RNA, SMALL INTERFERING; SMAD4 PROTEIN;

EID: 84923273195     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06424     Document Type: Article

References (31)

1. Nath, K. A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20, 1-17 (1992).
2. Becker, G. J. & Hewitson, T. D. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 9, 133-138 (2000).
3. Remuzzi, G. & Bertani, T. Pathophysiology of progressive nephropathies. N Engl J Med 339, 1448-1456 (1998).
4. Campanholle, G., Ligresti, G., Gharib, S. A. & Duffield, J. S. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. AmJ Physiol Cell Physiol 304, C591-603 (2013).
5. Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176, 85-97 (2010).
6. Lin, S. L., Kisseleva, T., Brenner, D. A. & Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173, 1617-1627 (2008).
7. Iwano, M. et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110, 341-350 (2002).
8. Kalluri, R. & Neilson, E. G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112, 1776-1784 (2003).
9. Li, J., Qu, X. & Bertram, J. F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin induced diabetic mice. Am J Pathol 175, 1380-1388 (2009).
10. Broekema, M. et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 18, 165-175 (2007).
11. Li, J., Deane, J. A., Campanale, N. V., Bertram, J. F. & Ricardo, S. D. The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis. Stem Cells 25, 697-706 (2007).
12. LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19, 1047-1053 (2013).
13. Hannon, G. J. RNA interference. Nature 418, 244-251 (2002).
14. Tijsterman, M., Ketting, R. F. & Plasterk, R. H. The genetics of RNA silencing. Annu Rev Genet 36, 489-519 (2002).
15. Dykxhoorn, D. M. & Lieberman, J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 56, 401-423 (2005).
16. Sledz, C. A. & Williams, B. R. RNA interference in biology and disease. Blood 106, 787-794 (2005).
17. Leung, R. K. & Whittaker, P. A. RNA interference: from gene silencing to genespecific therapeutics. Pharmacol Ther 107, 222-239 (2005).
18. de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6, 443-453 (2007).
19. Takabatake, Y. et al. Chemically modified siRNA prolonged RNA interference in renal disease. Biochem Biophys Res Commun 363, 432-437 (2007).
20. Shimizu, H. et al. siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol 21, 622-633 (2010).
21. Luo, G. H. et al. Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant Proc 40, 2365-2369 (2008).
22. Molitoris, B. A. et al. siRNA targeted to p53 attenuates ischemic and cisplatininduced acute kidney injury. J Am Soc Nephrol 20, 1754-1764 (2009).
23. Eddy, A. A. Molecular basis of renal fibrosis. Pediatr Nephrol 15, 290-301 (2000).
24. Boor, P. & Floege, J. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 38, 441-450 (2011).
25. Hamar, P. et al. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A 101, 14883-14888 (2004).
26. Ma, D. et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 20, 713-720 (2009).
27. Lewis, D. L. & Wolff, J. A. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev 59, 115-123 (2007).
28. Larson, S. D., Jackson, L. N., Chen, L. A., Rychahou, P. G. & Evers, B. M. Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery 142, 262-269 (2007).
29. van de Water, F. M. et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34, 1393-1397 (2006).
30. Meng, X. M. et al. Disruption of Smad4 impairs TGF-beta/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int 81, 266-279 (2012).
31. Ortega, A. et al. Role of parathyroid hormone-related protein in tubulointerstitial apoptosis and fibrosis after folic acid-induced nephrotoxicity. J Am Soc Nephrol 17, 1594-1603 (2006).